Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases-Reference-Cited by-同舟云学术

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases

Published:2022-01-10 Issue: Volume:2022 Page:1-3
ISSN:2090-6579
Container-title:Case Reports in Hematology
language:en
Short-container-title:Case Reports in Hematology

Author:

Molle Ingolf¹^ORCID,Petruskevicius Irma¹,Kamper Peter¹,d’Amore Francesco¹

Affiliation:

1. Department of Haematology, University Hospital of Aarhus, Aarhus, Denmark

Abstract

Treatment of early relapses of T lymphoblastic leukemia/lymphoma is often unsuccessful. We tested an experimental regimen containing daratumumab and nelarabine in two young patients with early relapses of T lymphoblastic lymphoma and T-ALL, respectively. Both patients achieved a deep complete remission. Combining daratumumab with chemotherapy may have a role in relapsing T lymphoblastic leukemia/lymphoma.

Publisher

Hindawi Limited

Subject

Cell Biology,Developmental Biology,Embryology,Anatomy

Link

http://downloads.hindawi.com/journals/crihem/2022/9722787.pdf

Reference11 articles.

1. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

2. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

3. Relapsed T Cell ALL: Current Approaches and New Directions

4. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

5. Will Daratumumab be the next game changer in early thymic precursor‐acute lymphoblastic leukaemia?

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute lymphoblastic leukaemia;Nature Reviews Disease Primers;2024-06-13

2. Daratumumab and Nelarabine Treatment as Salvage Therapy for T-Lymphoblastic Lymphoma: A Case Report;Biomedicines;2024-02-24

3. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions;Expert Review of Anticancer Therapy;2023-10-25

4. The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review;Frontiers in Oncology;2023-10-24

5. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults;Blood;2023-04-05